Scientists around the world are constantly looking for new methods to keep up and respond to a rapidly changing novel SARS-CoV-2 virus. Vaccines have been a huge success, but their global roll out has been slow and not equitable. 

To combat this, CanSino Biologics in China have developed an inhaled version of their COVID-19 vaccine, which has had early success in clinical trials. Two inhaled doses of the vaccine, given 28 days apart, produced a similar level of protection, measured by neutralising antibodies, to those of a single injection.

It's hoped that this technology will overcome some of the logistical challenges of a global vaccine rollout, getting more people protected, more rapidly.